New pill shows promise for deadly Post-Transplant blood disorder
NCT ID NCT07347990
First seen Jan 19, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study tests a new pill, iptacopan, for a rare but serious blood vessel condition called TA-TMA that can happen after a stem cell transplant. The drug aims to block harmful immune system activity and protect blood vessels. About 30 people who have not responded to initial treatments will take the pill and be monitored for up to 2 years to see if it improves survival and organ function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC MICROANGIOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China, 310003, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.